<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04604652</url>
  </required_header>
  <id_info>
    <org_study_id>HTD1801.PCT013</org_study_id>
    <nct_id>NCT04604652</nct_id>
  </id_info>
  <brief_title>Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis</brief_title>
  <acronym>PRONTO-PBC</acronym>
  <official_title>A Phase 2 Open Label, Proof of Concept Study of HTD1801 (BUDCA) in Adult Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to Standard Therapy - PRONTO-PBC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HighTide Biopharma Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HighTide Biopharma Pty Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this open-label study is to evaluate the safety and tolerability of HDT1801&#xD;
      (BUDCA) over 12 weeks in adult subjects with PBC who have an inadequate response to standard&#xD;
      therapy. Inadequate response is defined as persistently elevated serum alkaline phosphatase&#xD;
      at greater than or equal to1.5 times the upper limits of normal for the testing lab in spite&#xD;
      of having been on adequate doses of standard therapy with UDCA (ursodeoxycholic acid) at&#xD;
      13-15 mg/kg for at least 6 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 27, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single group open label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in alkaline phosphatase at Week 12 compared to Baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate the effects of HTD1801 (BUDCA) on serum alkaline phosphatase (ALP) in adult subjects with PBC who have experienced an inadequate response to standard therapy.&#xD;
Inadequate response is defined as ALP ≥1.5 × ULN despite having been on adequate doses of UDCA for at least 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum bilirubin from Baseline to Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate the effects of HTD1801 (BUDCA) on serum markers of cholestasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum gamma-glutamyl transferase (GGT) between Baseline and Week</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate the effects of HTD1801 (BUDCA) on serum markers of cholestasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum cholesterol (total and LDL) and triglyceride levels between Baseline and Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate the effects of HTD1801 on serum lipids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammatory serum markers including fibrinogen, CRP, Haptoglobin, ELF and serum immunoglobulins between Baseline and Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate the effects of HTD1801 (BUDCA) on serum markers of inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in GLOBE score between Baseline and Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate the safety and tolerability of HTD1801 over 12 weeks of treatment in adult subjects with PBC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pruritus as measured by Pruritus visual analog score (VAS) between Baseline and Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate the safety and tolerability of HTD1801 over 12 weeks of treatment in adult subjects with PBC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events and changes in physical examination, vital signs, and clinical laboratory values</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate the safety and tolerability of HTD1801 over 12 weeks of treatment in adult subjects with PBC</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Primary Biliary Cholangitis</condition>
  <condition>Primary Biliary Cirrhosis</condition>
  <condition>Cholangitis</condition>
  <condition>Cholestasis</condition>
  <condition>Biliary Tract Diseases</condition>
  <condition>Bile Duct Stricture</condition>
  <arm_group>
    <arm_group_label>Open-label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HTD1801 (BUDCA) 250 mg tablets. Dosed at 1000 mg BID with food.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTD1801 (BUDCA)</intervention_name>
    <description>HTD1801 (BUDCA) 250 mg tablets. Dose 1000 mg twice daily with food for 12 weeks.</description>
    <arm_group_label>Open-label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a clinical diagnosis of PBC as confirmed by patient history consistent with the&#xD;
             American Association for the Study of Liver Diseases (AASLD) Practice Guideline&#xD;
             confirmed by two of the following three criteria:&#xD;
&#xD;
               1. Biochemical evidence of cholestasis with elevation of ALP activity&#xD;
&#xD;
               2. Presence of antimitochondrial antibody (AMA)&#xD;
&#xD;
               3. Histopathologic evidence of non-suppurative cholangitis and destruction of small&#xD;
                  or medium-sized bile ducts if biopsy performed Note: historical AMA and liver&#xD;
                  biopsy data may be used but must be recorded in source documentation.&#xD;
&#xD;
          -  Has been taking a stable, adequate dose of at least (13-15 mg/kg/day) of UDCA for at&#xD;
             least 6 months with a serum ALP of at least ≥1.5 × ULN at any time after being on UDCA&#xD;
             for &gt;6 months (historical value) and at Screening. If the historical ALP was obtained&#xD;
             less than 6 months prior to study start as part of standard of care, the subject may&#xD;
             be screened and a second ALP value should be obtained as part of screening, There must&#xD;
             be at least a 4-week interval between the ALP values and the ALP values must be ≥1.5 ×&#xD;
             ULN&#xD;
&#xD;
          -  If the subject is taking cholestramine or other bile acid sequestrant for pruritus,&#xD;
             must be on a stable dose no more than once a day for at least 8 weeks prior to&#xD;
             Baseline visit. Must be willing and able to take cholestyramine at least 2 hours&#xD;
             before or after study medication&#xD;
&#xD;
          -  Females of child-bearing potential and males participating in the study must either&#xD;
             agree to use at least two approved barrier methods of contraception or be completely&#xD;
             abstinent from sexual intercourse, if this is their usual and preferred lifestyle,&#xD;
             throughout the duration of the study and for three months after stopping study drug.&#xD;
             Females who are postmenopausal must have appropriate documentation&#xD;
&#xD;
          -  Able to provide consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled concomitant autoimmune hepatitis (AIH). Subject should be on no more than&#xD;
             5 mg per day of prednisone (or equivalent dose for other corticosteroids) or no more&#xD;
             than 150 mg per day of azathioprine at stable doses and serum ALT should be ≤ 5 × ULN.&#xD;
             Enrollment of subjects with controlled AIH will be limited to a total of 5 subjects.&#xD;
&#xD;
          -  History of alcohol or substance abuse&#xD;
&#xD;
          -  Prior liver transplantation or currently listed for liver transplantation&#xD;
&#xD;
          -  History of chronic viral hepatitis, types B or C&#xD;
&#xD;
          -  Platelet count ≤150,000/mm3, albumin &lt;3.0 g/dL, International Normalized Ratio (INR)&#xD;
             &gt;1.2, or a history of ascites, or encephalopathy, or history of variceal bleeding&#xD;
&#xD;
          -  Total bilirubin &gt;1.3 × ULN unless subject has Gilbert Syndrome. If subject has&#xD;
             increased total bilirubin due to Gilbert's Syndrome, then direct bilirubin should be&#xD;
             &lt;0.3 mg/dL.&#xD;
&#xD;
          -  Hemoglobin &lt;10 g/dL for males or females&#xD;
&#xD;
          -  Serum TSH level &lt;0.1 or &gt;10 u/mL (subject may be re-screened if hyper- or&#xD;
             hypothyroidism has been corrected)&#xD;
&#xD;
          -  Renal impairment with eGFR &lt;60 ml/min (CKD stages 3, 4 or 5)&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV)-1 or HIV-2 infection by history&#xD;
&#xD;
          -  Glucose-6-phosphate dehydrogenase (G6PD) deficiency&#xD;
&#xD;
          -  History of malignancy within the past 2 years or ongoing malignancy other than basal&#xD;
             cell carcinoma, or resected noninvasive cutaneous squamous cell carcinoma&#xD;
&#xD;
          -  Active, serious infections that require parenteral antibiotic or antifungal therapy&#xD;
             within 30 days prior to Screening&#xD;
&#xD;
          -  Major surgical procedure within 30 days of Screening or prior solid organ&#xD;
             transplantation&#xD;
&#xD;
          -  Females who are pregnant or breastfeeding&#xD;
&#xD;
          -  Current or anticipated treatment with radiation therapy, cytotoxic chemotherapeutic&#xD;
             agents, and immune-modulating agents (such as interleukins, interferons)&#xD;
&#xD;
          -  Diseases that may result in increased serum ALP activities from sources other than the&#xD;
             biliary system (e.g., Paget's disease of bone, osteomalacia)&#xD;
&#xD;
          -  Allergy to the clinical trial material or its components&#xD;
&#xD;
          -  Having received any experimental medications within 28 days prior to Screening&#xD;
&#xD;
          -  Use of bezafibrate or fenofibrate within 28 days prior to first day of IP dosing&#xD;
&#xD;
          -  Use of obeticholic acid (OCA) within 28 days prior to first day of IP dosing&#xD;
&#xD;
          -  Any other clinically significant disorders or prior therapy that, in the opinion of&#xD;
             the investigator, would make the subject unsuitable for the study or unable to comply&#xD;
             with the dosing and protocol requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian DiBisceglie, MD</last_name>
    <role>Study Director</role>
    <affiliation>HighTide Therapeutics Biopharma Pty.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cathryn Bennett, BN</last_name>
    <phone>760-809-3523</phone>
    <email>cbennett@hightidetx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adrian DiBisceglie, MD</last_name>
    <phone>314-791-0593</phone>
    <email>adibisceglie@hightidetx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Inland Empire Clinical Trials</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Zeid Kayali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Schiff Center for Liver Disease</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cynthia Levy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Healthcare</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Roshan Shrestha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniel Pratt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greater Boston Gastroenterology</name>
      <address>
        <city>Framingham</city>
        <state>Massachusetts</state>
        <zip>01702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>George Dickstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FC Research</name>
      <address>
        <city>South Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas Vallone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health Services</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stuart Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Therapy and Advanced Research LLC</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Brian Borg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Brent Tetri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northshore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>David Bernstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University GI</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas Sepe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Robert Rahimi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eric Lawitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liver Institute of Virginia</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mitchell Shiffman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bon Secours Liver Institute of Richmond</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mitchell Shiffman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liver Institute Northwest</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kris Kowdley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 16, 2020</study_first_submitted>
  <study_first_submitted_qc>October 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2020</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Open-label</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholestasis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
    <mesh_term>Biliary Tract Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

